title: How much residual plasma may cause TRALI?
abstract: Although passive infusion of plasma-rich components containing white blood cell (WBC) antibodies are responsible for majority of the reported transfusion-related acute lung injury (TRALI) cases, the minimum volume of residual plasma, which might trigger TRALI, is not known. We report three cases of TRALI where the implicated donor component contained between 10 and 20 mL of residual plasma. Two cases were related to transfusion of red blood cells prepared in optimal additive solution, and the other was related to transfusion of pooled buffy coat platelets. In the latter case, WBC antibodies that matched the patient's human leucocyte antigen (HLA) antigens were only found in one buffy coat donor (female) who contributed a buffy coat for pooled platelets preparation. Plasma prepared from pooling platelets was collected from a male donor. Laboratory investigation confirmed that in all three cases, the donors' serum contained three to four different HLA class 1-specific and class 11-specific antibodies that matched with the patient's HLA type. Our cases suggest that the residual plasma volume as small as 10-20 mL containing donor derived WBC antibodies may cause TRALI. The risk of TRALI remains, despite providing pooled platelets suspended in male donor plasma. The significance of multiple HLA antigen/antibody matching between donor and recipient in immune TRALI warrants further study.
authors.affiliation: Red Cell Immunology Department, National Blood Service, Tooting Centre, London. nay.win@nhsbt.nhs.uk
authors.forename: N
authors.initials: N
authors.lastname: Win
authors.forename: C E
authors.initials: CE
authors.lastname: Chapman
authors.forename: K M
authors.initials: KM
authors.lastname: Bowles
authors.forename: A
authors.initials: A
authors.lastname: Green
authors.forename: S
authors.initials: S
authors.lastname: Bradley
authors.forename: D
authors.initials: D
authors.lastname: Edmondson
authors.forename: J P
authors.initials: JP
authors.lastname: Wallis
mesh_terms: D055371:Acute Lung Injury / Q000209:etiology* / Q000517:prevention & control; D000293:Adolescent; D000369:Aged, 80 and over; D001782:Blood Donors; D017707:Erythrocyte Transfusion / Q000009:adverse effects*; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007518:Isoantibodies / Q000009:adverse effects* / Q000097:blood / Q000276:immunology; D007962:Leukocytes / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010949:Plasma / Q000276:immunology*; D017713:Platelet Transfusion / Q000009:adverse effects*
chemical_list: D006680:HLA Antigens; D007518:Isoantibodies